Calliditas Therapeutics AB (publ)
CALT · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $7 | $5 | $6 | $6 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $1 | $1 | $0 | $0 |
| Enterprise Value | $7 | $4 | $5 | $5 |
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 50.3% | 250.1% | 26,141.1% | – |
| Gross Profit | $1 | $1 | $0 | $0 |
| % Margin | 93.6% | 98.1% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -30.5% | -48.4% | -205.7% | -43,409.4% |
| Net Income | -$0 | -$0 | -$1 | -$0 |
| % Margin | -38.6% | -51.3% | -222.2% | -49,944.1% |
| EPS Diluted | -17.38 | -15.56 | -20.04 | -19.46 |
| % Growth | -11.7% | 22.4% | -3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |